Synthesis and evaluation of coumarin derivatives against human lung cancer cell lines

K.-G. Weng¹ and Y.-L. Yuan²

¹Department of Radiation Oncology, Chongqing Cancer Institute and Hospital and Cancer Center, Chongqing, China
²Department of Clinical Laboratory, Chongqing the Seventh People’s Hospital, Chongqing, China

Abstract

Series of novel coumarin derivatives [I (a–d) and II (a–d)] were successfully synthesized and their structures were determined based on infrared 1H-nuclear magnetic resonance (NMR), HRMS, and single crystal X-ray crystallography. Additionally, the new synthesized compounds were evaluated to identify the molecular characteristics that contribute to their cytotoxicity, which was tested against SK-LU-1, SPC-A-1 and 95D human lung cancer cell lines, using the MTT assay. The results of this study showed that compounds Ic, Id, IIc, and IId exhibited an efficient percentage of inhibition of cell proliferation.

Key words: Coumarin; X-ray; Lung cancer

Introduction

Cancer is the leading cause of death in developed countries and the second leading cause of death in developing countries (1–3). Currently, the traditional therapies of surgery, chemotherapy and radiation play an important role in the systemic treatment of cancer (4–6). However, the treatment outcome is generally poor. Thus, it is very important to find an effective alternative treatment for cancer (7–9).

Coumarins are an important class of compounds of both natural and synthetic origin. Many compounds that contain the coumarin moiety exhibit useful and diverse pharmaceutical and biological activities, and there has been a growing interest in their synthesis (10–12). Some of these coumarin derivatives have been found useful in photochemotherapy, antitumor and anti-HIV therapy, as CNS-stimulants, antibacterial, anticoagulant, antifungal, and antioxidant agents, and as dyes (13–15). Natural, semi-synthetic and synthetic coumarins are useful substances in drug research. Coumarins can be used not only to treat cancer, but also to treat the side effects caused by radiotherapy (16–18). In this paper, series of coumarin derivatives [I (a–d) and II (a–d)] (Figure 1) have been synthesized and their potential antitumor activity was investigated.

Material and Methods

Apparatus and materials

To obtain infrared (IR) spectra (400–4000 cm⁻¹), we used a Brucker Equinox-55 spectrophotometer (Bruker, Germany), to obtain 1H-nuclear magnetic resonance (NMR) spectra we used a Varian Inova-400 spectrometer (Varian USA; at 400 MHz), and for the Mass spectra, we used a micrOTOF-Q II mass spectrometer (Bruker, Germany). The melting points were taken on a XT-4 micro melting apparatus (Ledon, China), and the thermometer was uncorrected.

Synthesis and characterization of compounds I (a–d) and II (a–d)

Compounds I (a–d) were synthesized according to the methods of a previous report (19). A mixture of aromatic aldehydes (10 mmol) and 4-hydroxycoumarin (20 mmol) was dissolved in 100 mL of acetic anhydride (Ac2O). A few drops of piperidine were added, and the mixture was stirred for 3 h at room temperature. After reaction completion, determined by thin-layer chromatography, water was added until precipitation occurred. After filtering the precipitates, they were sequentially washed with ice-cooled water and ethanol and then dried in a vacuum.

I a. 7H-pyrano[3,2-c;5,6-c]dichromene-6,8-dione: 279–280°C. IR (KBr pellet cm⁻¹): 3432, 2844, 1943, 1564, 1108 cm⁻¹. 1H NMR (DMSO-d6, δ, ppm): 7.912–7.960 (m, 2H), 7.562–7.647 (m, 2H), 7.321–7.389 (m, 4H), 3.789 (s, 1H), 3.680 (s, 1H). HRMS (ESI+): m/z: calcd for C19H10O5: 341.0420 [M+Na]+; found: 341.0419.

I b. 7-(3,4-dimethyl-phenyl)-7H-pyran[3,2-c;5,6-c]dichromene-6,8-dione: > 300°C. IR (KBr pellet cm⁻¹): 3433, 2834, 1870, 1581, 1060 cm⁻¹. 1H NMR (DMSO-d6, δ, ppm):
8.388–8.407 (d, 2H), 7.747–7.765 (t, 2H), 7.497–7.567 (m, 4H), 7.127 (s, 1H), 7.066–7.085 (d, 1H), 7.059–7.029 (d, 1H), 4.803 (s, 1H), 2.127–2.137 (d, 6H). HRMS (ESI+): m/z: calculated for C27H18O5: 445.1046 [M+Na]+; found: 445.1098.

Ic. 7-(4-chloromethyl-phenyl)-7H-pyrano[3,2-c;5,6-c]dichromene-6,8-dione: 430°C. IR (KBr pellet cm⁻¹): 3390, 2731, 1771, 1479, 1075 cm⁻¹. 1H NMR (DMSO-d6, δ, ppm): 8.405–8.428 (q, 2H), 7.757–7.800 (m, 2H), 7.506–7.578 (m, 4H), 7.403–7.424 (d, 2H), 7.329–7.350 (d, 2H), 4.899 (s, 1H), 4.701 (s, 2H). HRMS (ESI+): m/z: calculated for C26H15ClO5: 465.0500 [M+Na]+; found: 465.0564.

Id. 7-(3,4-dichloro-phenyl)-7H-pyrano[3,2-c;5,6-c]dichromene-6,8-dione: 430°C. IR (KBr pellet cm⁻¹): 3329, 2853, 1799, 1521, 1120 cm⁻¹. 1H NMR (DMSO-d6, δ, ppm): 8.393–8.421 (q, 2H), 7.753–7.806 (m, 3H), 7.501–7.578 (m, 6H), 4.891 (s, 1H), 4.701 (s, 2H). HRMS (ESI+): m/z: calculated for C25H12Cl2O5: 484.9954 [M+Na]+; found: 484.9919.

The synthesis method for compounds II (a–d) was similar to that of compounds I (a–d), in which Ac2O solvent was replaced by ethanol.

II a. 3,3'-((3,4,5-trimethoxyphenyl)methylene)bis(4-hydroxy-2H-chromen-2-one): 211–212°C. IR (KBr pellet cm⁻¹): 3066, 2672, 1912, 1654, 987 cm⁻¹. 1H NMR (CDCl3, δ, ppm): 11.586 (s, 1H), 11.310 (s, 1H), 8.048–8.052 (d, 2H), 7.641–7.684 (m, 2H), 7.431–7.452 (d, 4H), 6.441–6.443 (d, 2H), 6.097 (s, 1H), 3.873 (s, 3H), 3.742 (s, 6H). HRMS (ESI+): m/z: calculated for C28H22O9: 525.1156 [M+Na]+; found: 525.1177.

II b. 3,3'-((4-diethylamino)phenyl)methylene)bis(4-hydroxy-2H-chromen-2-one): 221–222°C. IR (KBr pellet cm⁻¹): 3411, 2732, 1878, 1675, 1219 cm⁻¹. 1H NMR (CDCl3, δ, ppm): 8.033–8.061 (m, 2H), 7.615–7.651 (t, 2H), 7.379–7.432 (q, 4H), 7.039–7.060 (d, 2H), 6.634–6.655 (d, 2H), 6.048 (s, 1H), 3.324–3.376 (q, 4H), 1.145–1.180 (t, 6H). HRMS (ESI+): m/z: calculated for C29H25NO6: 506.1574 [M+Na]+; found: 506.1519.

II c. 3-(bis(4-hydroxy-2-oxo-2H-chromen-3-yl)methyl)benzonitrile: 242–243°C. IR (KBr pellet cm⁻¹): 3066, 2754, 1912, 1654, 987 cm⁻¹. 1H NMR (CDCl3, δ, ppm): 11.564 (s, 1H), 11.353 (s, 1H), 7.996–8.094 (q, 2H), 7.649–7.688 (t, 2H), 7.575–7.593 (t, 1H), 7.390–7.507 (m, 7H), 6.069 (s, 1H). HRMS (ESI+): m/z: calculated for C26H15NO6: 460.0792 [M+Na]+; found: 460.0766.

II d. 3,3'-((4-chloro-3-(trifluoromethyl)phenyl)methylene)bis(4-hydroxy-2H-chromen-2-one): 219–220°C. IR (KBr pellet cm⁻¹): 3011, 2875, 2000, 1765, 1101 cm⁻¹. 1H NMR (CDCl3, δ, ppm): 11.568 (s, 1H), 11.384 (s, 1H), 8.017–8.121 (q, 2H), 7.668–7.707 (t, 2H), 7.355–7.519 (m, 7H), 6.079 (s, 1H). HRMS (ESI+): m/z: calculated for C26H14ClF3O6: 537.0323 [M+Na]+; found: 537.0398.

Crystal structure determination

According to the evaporation of chloroform solution, suitable single crystals of compound I b became available. The diffraction data were acquired on a Bruker Smart Apex CCD area detector using a graphite monochromated Mo Kα radiation (λ=0.71073 Å) at room temperature. The structure was solved by using the program SHELXL-97 (20) and Fourier difference techniques, and refined by full-matrix least-squares method on F2. Hydrogen atoms attached to carbon were placed in geometrically idealized positions and refined using a riding model.
Crystallographic data for compound I b are reported in Table 1.

Table 1. Crystal data and structure refinements for compound I b.

| Parameter | Value |
|-----------|-------|
| Formula   | C27H18O5·CHCl3 |
| Mr        | 541.78 |
| Temperature/K | 293 (2) |
| Crystal system | Monoclinic |
| Space group | P21/c |
| a/Å       | 15.1120 (16) |
| b/Å       | 11.8560 (12) |
| c/Å       | 14.6020 (14) |
| α/°       | 90 |
| β/°       | 111.633 (6) |
| γ/°       | 90 |
| V/Å³      | 2431.9 (4) |
| Z         | 4 |
| Dcalc/g·cm⁻³ | 1.480 |
| μ(Mo Kα)/mm⁻¹ | 3.745 |
| θ range/° | 3.15 to 72.74 |
| Reflections collected | 26067 |
| No. unique data [R(int)] | 4754 [0.0625] |
| No. data with I ≥ 2σ(I) | 4278 |
| R1        | 0.0487 |
| wR2 (all data) | 0.1182 |

Cytotoxicity assay

The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay was performed as described previously (21). Cells were seeded onto a 96-well plate at a concentration of 10⁴ cells/well and allowed to adhere overnight. Five replicates were prepared for each treatment and cultured for 48 or 72 h. After 20 μL of MTT (5 mg/mL) was added to each well, the cells were cultured for another 4 h. The supernatant was discarded. After 150 μL of DMSO was added to each well, the samples were incubated at 37°C for 30 min and then swirled for 10 min. The absorbance at 570 nm was measured using a microplate reader. Experiments were repeated three times.

Results and Discussion

Molecular structure

In order to confirm the configuration of the product, single crystals of compound I b were cultured for X-ray diffraction analysis. The crystal structure of compound I b is given in Figure 2. One can see a chloroform solvent molecule incorporated in the asymmetric unit. In general, the molecular dimensions of the title compound agree with the corresponding values of other similar compounds (9). In the title crystal structure, two 4-hydroxycoumarin moieties are linked through a methylene bridge, wherein

Figure 2. Molecular structure of compound I b.
one hydrogen atom has been replaced with a 3,4-dimethylphenyl residue. Two hydroxyl groups form an ether bond by releasing a water molecule. This results in the formation of a big, essential planar heterocyclic ring system with 4.349° and 5.217° dihedral angle between the newly formed ether ring and the two original coumarin rings, respectively. The dihedral angle between the mean planes of the heterocyclic ring system and the 3,4-dimethylphenyl ring is 87.219°.

The crystal packing structure along the a axis is shown in Figure 3. Its crystal structure represents a three-dimensional supra-molecular network. Within the three-dimensional structure, there is one type of C–H...O; a hydrogen bonding is observed among these organic ligands. Detailed information of C–H...O hydrogen bonding is reported in Table 2. In other words, the three-dimensional supra-molecular framework was generated by means of the C–H...O hydrogen bonding interactions.

**Pharmacology**

The synthesized compounds I (a–d) and II (a–d) were screened *in vitro* for their antitumor activities against SK-LU-1, SPC-A-1 and 95D human lung cancer cell lines using the standard MTT method, with the antitumor drug docetaxel used as a positive control. The *in vitro* cytotoxicity screening assays were conducted at different

---

**Figure 3.** Crystal packing structure of compound I b along the a axis.
Table 3. *In vitro* anti-proliferative activity of I (a–d) and II (a–d) against human cancer cell lines.

| Compounds | IC50 (μM) | SK-LU-1 | SPC-A-1 | 95D |
|-----------|-----------|---------|---------|-----|
| I a       | >100      | >100    | >100    |     |
| I b       | >100      | >100    | >100    |     |
| I c       | 20        | 20      | 23      |     |
| I d       | 25        | 25      | 21      |     |
| II a      | >100      | >100    | >100    |     |
| II b      | >100      | >100    | >100    |     |
| II c      | 20        | 21      | 25      |     |
| II d      | 22        | 20      | 23      |     |
| Doxorubicin| 25        | 30      | 25      |     |

Table 2. Hydrogen bonds information (Angstrom, Deg).

| D–H...A | D–H | H...A | D...A | D–H...A |
|---------|-----|------|-------|---------|
| C11–H11...O4 | 0.9500 | 2.5400 | 3.1714 | 124.00 |
| C27–H27...O2 | 0.9800 | 2.5300 | 3.143  | 121.00 |
| C28–H28...O2 | 1.0000 | 2.1700 | 3.079  | 150.00 |

from the percentage of cytotoxicity by nonlinear curve fitting and are presented in Table 3.

Among all of the investigated compounds, I c, I d, II c and II d exhibited the most potent growth inhibition in the three lung cancer cells, with an IC50 value of 20–25 μM, indicating that they are more potent than docetaxel, which exhibited an IC50 value of 25–30 μM. In contrast, other compounds exhibited significantly weaker activity, because the cytotoxicity was lower than that of docetaxel in the three cell lines, with an IC50 value of >100 μM.

In conclusion, among the coumarin compounds that we successfully synthesized, compounds I c, I d, II c and II d had a strong electron-withdrawing group (-CH2Cl, -Cl, -CN and -CF3) in the phenyl ring with the highest cytotoxic activity against the cancer cell lines tested. Therefore, the four compounds are potential anticancer drugs, yet further tests are required to determine their *in vivo* antitumor activity.

References

1. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. *In vitro* anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. *Cancer Chemother Pharm* 2007; 59: 589–601, doi: 10.1007/s00280-006-0300-z.

2. Yi Y, Liao ST, Zhang MW, Zhang RF, Deng YY, Yang B, Wei ZC. Immunomodulatory activity of polysaccharide-protein complex of longan (Dimocarpus longan Lour.) pulp. *Molecules* 2011; 16: 10324–10336, doi: 10.3390/molecules16210324.

3. Ting Min, Jie Sun, Yang Yi, Hong-Xun Wang, Fei Hang, You-Wei Ai, Li-Mei Wang. Microanalysis, Pharmacokinetics and Tissue Distribution of Polysaccharide-Protein Complexes from Longan Pulp in Mice. *Int J Mol Sci* 2015; 16: 24403–24416, doi: 10.3390/ijms16102403.

4. Zarranz B, Jaso A, Aldana I, Monge A. Synthesis and antican- cer activity evaluation of new 2-alkylcarbonyl and 2-benzoyl-3-trifluoromethyl-quinazoline 1,4-di-N-oxide derivatives. *Bioorg Med Chem* 2004; 12: 3711–3721, doi: 10.1016/j.bmc.2004.04.013.

5. Smith NF, Figg WD, Sparreboom A. Recent advances in pharmacogenetic approaches to anticancer drug development. *Drug Develop Res* 2004; 62: 233–253, doi: 10.1002/ddr.10361.

6. Sloan KB, Wasdo S. Designing for topical delivery: Prodrugs can make the difference. *Med Res Rev* 2003; 23: 763–793, doi: 10.1002/med.10048.

7. Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S, et al. Anti-Tumor Activity of a Novel Compound-CDF Is Mediated by Regulating miR-21, miR-200, and PTEN in Pancreatic Cancer. *PLoS One* 2012; 6: e17850, doi: 10.1371/journal.pone.0017850.

8. Yu H, Huang Q. Enhanced *in vitro* anti-cancer activity of curcumin encapsulated in hydrophobically modified starch. *Food Chem* 2010; 119: 669–674, doi: 10.1016/j.foodchem.2009.07.018.

9. Wang YC, Bachrach U. The specific anti-cancer activity of green tea (-)-epigallocatechin-3-gallate (EGCG). *Amino Acids* 2002; 22: 131–143, doi: 10.1007/s007260200002.

10. Li J, Xue X, Li X, Hou Z, Yang X, Qu D, et al. Synthesis of biscoumarin and dihydropyran derivatives as two novel classes of potential anti-bacterial derivatives. *Arch Pharm Res* 2016; 39: 1349–1355, doi: 10.1007/s12272-015-0614-7.

11. Li J, Sui YP, Xin JJ, Du XL, Li JT, Huo HR, et al. Synthesis of biscoumarin and dihydropyran derivatives with promising antitumor and antibacterial activities. *Bioorg Med Chem Lett* 2005; 25: 5520–5523, doi: 10.1016/j.bmcl.2015.10.063.

12. Nofal ZM, Elzahar MI, Elkarnin SSA. Novel Coumarin Derivatives with Expected Biological Activity. *Molecules* 2000; 5: 99–113, doi: 10.3390/molecules1610200099.

13. Luo K, Wu F, Zhang D, Dong R, Fan Z, Zhang R, Yan Z, Wang Y, Zhang J. Transcriptomic profiling of Melilotus albus near-isogenic lines contrasting forcoumarin content. *Sci Rep* 2017; 7: 4577, doi: 10.1038/s41598-017-04111-y.
14. Chen LZ, Sun WW, Bo L, Wang JQ, Xiu C, Tang WJ, Shi JB, Zhou HP, Liu XH. New arylpyrazoline-coumarins: Synthesis and anti-inflammatory activity. *Eur J Med Chem* 2017; 138: 170–181, doi: 10.1016/j.ejmech.2017.06.044.

15. Kontogiorgis CA, Hadjipavlou-Litina DJ. Synthesis and anti-inflammatory activity of coumarin derivatives. *J Med Chem* 2005; 48: 6400–6408, doi: 10.1021/jm0580149.

16. Lee S, Sivakumar K, Shin WS, Xie F, Wang Q. Synthesis and anti-angiogenesis activity of coumarin derivatives. *Bioorg Med Chem Lett* 2006; 37: 4596–4599, doi: 10.1002/bcm.200651115.

17. Li J, Lv CW, Li XJ, Qu D, Hou Z, Jia M, et al. Synthesis of biscoumarin and dihydropyran derivatives and evaluation of their antibacterial activity. *Molecules* 2015; 20: 17469–17482, doi: 10.3390/molecules200917469.

18. Tan S, He F, Kong T, Wu J, Liu Z. Design, synthesis and tumor cell growth inhibitory activity of 3-nitro-2H-chromene derivatives as histone deacetylases inhibitors. *Bioorg Med Chem* 2017; 25: 4123–4132, doi: 10.1016/j.bmc.2017.05.062.

19. Yamaguchi Y, Nishizono N, Kobayashi D, Yoshimura T, Wada K, Oda K. Evaluation of synthesized coumarin derivatives on aromatase inhibitory activity. *Bioorg Med Chem Lett* 2017; 27: 2645–2649, doi: 10.1016/j.bmcl.2017.01.062.

20. Sheldrick GM. SHEXL-97, program for solution crystal structure and refinement. Götingen: University of Götingen; 1997.

21. Kupcsik L. Estimation of cell number based on metabolic activity: the MTT reduction assay. *Methods Mol Biol* 2011; 740: 13–19, doi: 10.1007/978-1-61779-108-6_3.